Bristol Myers Squibb and 2seventy bio, Inc. received approval from the U.S. FDA for Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody, based on results from the KarMMa-3 trial.    This approval expands Abecma’s indication, making it available in earlier lines to patients who have re...